Episode 1: Our Rating Action On Gilead
In this episode, healthcare analysts Arthur Wong and Adam Dibe discuss the rationale behind our recent rating action on biopharmaceutical company Gilead and field investors' questions concerning the company, including growth expectations and its capacity for acquisitions.